Novartis Ag (NVS) EBITDA (2009 - 2026)

Novartis Ag has disclosed EBITDA across 18 years of filings, most recently posting $4.8 billion for Q2 2026.

• In Q2 2026, EBITDA fell 2.34% year-over-year to $4.8 billion; the TTM figure through Jun 2026 stood at $23.0 billion (up 12.03% YoY), while the FY2025 annual figure was $17.6 billion, up 21.31% from the prior year.
• EBITDA came in at $4.8 billion for Q2 2026 at Novartis Ag, up from $4.2 billion in the prior quarter.
• In the past five years, EBITDA ranged from a high of $9.5 billion in Q4 2025 to a low of $1.8 billion in Q3 2023.
• Average EBITDA over 5 years is $4.6 billion, with a median of $4.6 billion recorded in 2025.
• Year-over-year, EBITDA plunged 43.52% in 2022 and surged 105.85% in 2024.
• Over 5 years, EBITDA stood at $6.2 billion in 2022, then advanced by 16.09% to $7.2 billion in 2023, then rose by 2.78% to $7.4 billion in 2024, then rose by 28.97% to $9.5 billion in 2025, then slumped by 50.14% to $4.8 billion in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $4.8 billion in Q2 2026, $4.2 billion in Q1 2026, and $9.5 billion in Q4 2025.